Abalos Therapeutics to Share Preclinical Findings at SITC 2025 Underscoring ABX-001’s Potent, Synergistic Impact When Combined with Bispecific T-cell Engagers

— Combining with bispecific T-cell engagers significantly boosts T-cell recruitment and cell-killing activity against tumor cells —

Düsseldorf, Germany, November 4, 2025 – Abalos Therapeutics announced today that it will unveil new preclinical findings concerning the development of ABX-001 and its potential to further amplify anti-tumoral effects when paired with bispecific T-cell engagers. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Professor Karl S. Lang, PhD, Chair of Immunology at the Medical Faculty, University Duisburg-Essen and Scientific Founder of Abalos, is scheduled to present the data during the poster session on Saturday, November 8, at 12:15 pm ET. ABX-001 is Abalos’ primary therapeutic candidate, having demonstrated robust anti-cancer efficacy across various clinically relevant solid tumor models. The company recently revealed the commencement of a Phase 1 first-in-human trial assessing ABX-001 as a monotherapy in patients with advanced solid tumors that are refractory or relapsed.

“By harnessing the inherent processes of mutation and selection, coupled with targeted virus engineering, we have developed an immunotherapy with highly distinct immunostimulatory and anti-tumoral characteristics,” stated Jörg Vollmer, CSO at Abalos. “These new preclinical results show that ABX-001 collaborates effectively with T-cell directed therapies, such as bispecific T-cell engagers, to generate a potent synergistic anti-tumor response. This synergy could potentially lead to more lasting and efficacious treatments for patients with solid tumors, where current immunotherapies frequently fall short.”

Presentation Details:

Poster Presentation
Abstract Title: Optimized arenavirus vectors with tumor-tropic mutations as new class of amplificators of anti-tumoral T-cell responses
Abstract Number: 828
Date: Saturday, November 8, 2025
Presenter: Prof. Karl S. Lang, PhD, Chair of Immunology at the Medical Faculty, University Duisburg-Essen and Scientific Founder of Abalos

Abalos developed ABX-001 as a therapeutic agent by refining a non-lytic arenavirus strain through the strategic selection of specific mutations combined with advanced virus engineering to achieve immunostimulatory and anti-tumoral properties. In both in vivo and in vitro experiments, ABX-001 exhibited preferential replication within tumor cells, with minimal impact on healthy tissues. ABX-001 actively recruits, activates, and expands CD8+ T-cells, thereby increasing tumor infiltration and inducing the differentiation of these T-cells into potent effector cells capable of strong anti-tumoral activity. Furthermore, treatment with ABX-001 proved safe, showing no severe adverse effects in immune-compromised mice or non-human primates. Critically, when administered alongside a bispecific T-cell engager, ABX-001 yielded synergistic anti-tumor effects, substantially enhancing T-cell recruitment and cytotoxic activity against tumor cells compared to bispecific T-cell engager therapy alone.
  

About Abalos Therapeutics
Abalos Therapeutics is pioneering a novel anti-cancer strategy that precisely directs the full scope of the immune system’s power toward cancer cells. Abalos’ arenavirus-based drug candidates are engineered to trigger precise innate and adaptive immune responses from within the tumor environment. They engage all relevant immune cell types in a coordinated assault against both the primary tumor and distant metastases, actively guiding them into the cancerous tissue. Abalos’ lead product candidate, ABX-001, has demonstrated robust anti-tumor efficacy in pre-clinical studies across multiple tumor models, as well as an excellent pre-clinical safety profile, and is now being evaluated in a Phase 1 trial for various solid tumors. Under the leadership of experienced biotech entrepreneurs and immunology pioneers, Abalos’ mission is to establish a new category of drugs in immuno-oncology. For further details, please visit .

For more information, please contact:

Abalos Therapeutics GmbH
Phone: +49 211 540104-0
Email:

Abalos media inquiries
Trophic Communications
Stephanie May / Eva Mulder
Phone: +49 171 185 56 82
Email:

Attachment